Despite the clinical guidelines’ recommendation of using PD-(L)1 inhibitor-based regimens as the standard-of-care first-line treatment options for patients with advanced NSCLC [19, 20], platinum-based chemotherapy was still commonly used as the initial treatment, although there was a decreasing trend over time. This evidence concerns the gene CD274 and non-small cell lung carcinoma.